The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Thank you Manifesto. That is very clear. However it seems to me that they still have to sustain most of the loss. For example.
Business A makes £10m annual profit. Corporation Tax @ 19% = £1.9m
Business B makes £10m profit on one revenue stream but offsets an £8m losses from another source against it. The net profit is £2m with £380K payable in Corporation Tax.
Although Business B sustains losses of £8m, only £1.52m of these losses are recoverable through offsetting them against Corporation Tax.
My example is a vast over simplification. However I don't see how Polar Capital haven't sustained a net loss if they have sold their Synairgen shareholding well below their purchase price?
Regards and good wishes.
"They can offset their losses against their profits"
What does this mean for Polar Capital? Is it that they pay less corporation tax due to a reduced net profit?
I have just attempted a "dummy" buy just before close of trading. It was possible to purchase 100,000 shares @ 24p. Can anyone offer an explanation?
Docdaneeka.
Although, your long post earlier today leaned on the pessimistic side, I found myself agreeing with most of your points as I read through them. Your subsequent short post sums up my aspirations for my investment in a nutshell.
There are still too many unknowns at present, and I hope that the company will quickly get on with the job of cleaning up the mess that the recent RNS has created. Time is of the essence in my opinion. They do not have the luxury of taking an unreasonably long amount of time to comprehensively analyse, and publish detailed outcomes from, the data set. Like you, I hope that they will uncover sufficient data to pass the baton to a larger entity who has the wherewithal to bring SNG001 to market as quickly as possible.
My best wishes to you, and to all Synairgen investors.
Good post Size82, crystallising the optimism that deeply underwater long-term investors still hold. The answers that you are seeking will eventually arrive. Wigster77 has added some justified realism to the timeline, which I endorse having read my Synairgen notes again yesterday evening. Sadly, each time I see Richard Marsden's name on company documents, it evokes that famous quote from Barak Obama regarding Joe Biden's competence prior the the 2020 USA Presidential elections.
This is one of the reasons why I am hoping that any pearls, emerging from the data deep dive, will prompt a takeover bid for the company. The latter would result in a win-win for all concerned. But first we need the quality data in order to tempt predatory pharmaceutical companies to make a move.
With my best wishes to all Synairgen investors.
Bruce.
"Mighty oaks from little acorns grow".
This could well be the case if SNG001 is comprehensively managed by a large pharmaceutical company.
Regards and good wishes.
I believe that I may have launched the buyout conundrum as part of a comment yesterday? I may have been somewhat obtuse, but believe that I stated that a buyout proposal would only arise if the amalgamated and enhanced data from Synairgen trials showed promise. Should this tempt a large pharma to make a bid, they might tempt Polygon with an offer matching their highest buy price or better? Presumably, a similar offer would need to be made to all other investors?
Pure speculation from me, but I am currently addressing all possible positive scenarios.
I'm not sure about that altube. Recently, a contributor affirmed that the offer would need to match the highest price paid by the buyer during the last 12 months. This could be 200p+?
Regards and good wishes.
Thanks Fruitsnveg.
Your article confirms the information in Tommy's earlier post. My interest here mostly lies with the fact that the USA have yet to decide on a way forward with complementary therapies to the vaccination programme. This keeps the Synairgen boat afloat in the current sea of uncertainty.
Regards and good wishes.
Thank you Tommy. Your article clarifies the USA's hesitation in prescribing Evusheld - at a time when Omicron was in the ascendancy.
Regards and good wishes.
I was about to respond to his/her usual negativity, when yet another dollop of negativity introduced by RosieNas and backed up by pillow was taken down. Why do these individuals bother if they are not invested?
My original reply:
RosieNas does this sort of thing on other bulletin boards. It probably floats her particular boat. The following "rockabilly" song applies to RosieNas, the spreader of "rock bottom" doom and gloom forecasts on investor forums.
https://www.youtube.com/watch?v=mJZYXbpErvc
This article is from today's New York Times. With apologies if it has already been presented here. It shows that the USA Government is still confused and undecided as to the best route forward from the pandemic.
Evusheld, a new treatment developed by AstraZeneca, can prevent Covid-19 in people who either cannot produce antibodies after being vaccinated or cannot be vaccinated at all. Administered in two consecutive injections, it appears to offer as much as six months of protection to immunocompromised people, giving it considerable appeal for those who have had to continue to stay home even as the U.S. reopens.
But there is so much confusion about the drug among health care providers that roughly 80 percent of the available doses in the U.S. are sitting unused — even as patients go to great lengths, often without success, to get them. In some cases, patients and doctors do not know that Evusheld exists or how to get it. Government guidelines on whom should receive the treatment are scant.
Hesitance is an issue, too. Some providers do not know how to use Evusheld and are thus loath to prescribe it. The fact that it is an antibody treatment can be confusing, because most such treatments are used after someone gets Covid rather than for preventive care. And in some medical centers, supplies are reserved only for patients at the highest risk, such as recent transplant recipients and cancer patients.
The Biden administration has purchased 1.7 million doses — enough to fully treat 850,000 people — and had nearly 650,000 doses ready for distribution as of this past week, according to federal health official. But only about 370,000 doses have been ordered by the States, and fewer than a quarter of those have been used.
Apologies. Feb 21
TLW
Trinityman.
Thank you for re-posting Beforegolf's summary, and adding some useful comments of your own. An excellent synthesis of where we are, and what might be achievable? Like you, I fail to understand why the share price plunged by 93% in minutes when the market opened on May 21? I actually bought more on that day, when the share price was slightly higher than it is at present. This is because I firmly believe in the consistent scientific information that I have read over the last seventeen months or so. I hope that the company will do what is necessary to make reparations once it has the necessary data to present an enhanced analysis to the market.
I am happy that the general consensus on this board has shifted from initial despondence to an expectation of a recovery once the company have their strategy in place. It is impossible to project a time frame, but I now see the various possibilities as we progress from here.
Regards and good wishes to you and all synairgen investors.
Significant combined data outcomes from Synairgen's three trials are the best investors can look forward to for the time being. The fact that ACTIV-2 Phase 3 has been paused until further notice suggests that even if the latter does go ahead, with the reduced number of infected individuals, it could take a long time to conduct the actual trial.
A number of questions have arisen recently, these being:
1. Why is it taking so long to release the analysed ACTIV-2 Phase 2 data? Contributors to this board have looked at the time line of a similar trial, and it is reasonable to suggest that the data should be with the company sooner than the time announced in last week's RNS?
2. Could the promising results of recent in vitro studies released last week have been announced sooner? If so, did the company keep them back to be released with the Sprinter data (which they anticipated to be more successful than was actually achieved)?
3. Should the combined data from company trials above prove to be a fruitful amalgam, will it be sufficient for the company to proceed with the next steps? Alternatively would it stimulate a large pharmaceutical company to contemplate an offer for the entire company?
4. What would constitute a fair offer for the company at the present time? Contrary to the thoughtless comments from outsiders on this board, SNG001 is very much in the frame. In my view, it just needs further data to demonstrate its efficacy unequivocally.
5. Should the outcome of Synairgen's ongoing data analysis prove to be fruitful, what would happen subsequently? Would further trials be necessary? Are platform trials still in the frame, or will they be withdrawn for the time being bearing in mind the reduction in infections and hospitalisations?
6. What are Polygon's plans? They currently own 25% of Synairgen. Are they going to trade in the current climate to keep the share price low as they continue to add? Are they aiming at a stake just short of the 30% that would necessitate a bid for the company governed by defined protocols? Could they act as Kingmakers i.e. sell their entire holding to a large pharmaceutical company who might wish to acquire Synairgen for a considerably lower price than might have been the case with the expected Sprinter trial outcomes ? [My guess at a fair price range would be 155-175p, provided the re-analysed data shows promise? Now would be a perfect time to make such an offer, which many long term holders would accept in the present uncertain times. We have trusted the company previously. It would be difficult for them to galvanise investors against accepting a reasonable offer at the present time?]
There is a great deal to think about at the current time. My thoughts are simplistic, and it is vital to maintain a positive outlook. I will continue to monitor this board. Currently my screen displays more "green coffins" during trading times than ever before, with good reason.
My best wishes to all Synairgen investor
quasar.
Why are you bothering in attempting to execute a Motley Fool style, light touch hatchet job on Synairgen to an audience who are currently suffering considerable loss in the value of their shareholdings? Surely a general share trader forum on Facebook, or a similar platform, would be more appropriate for this type of comment. Your are evidently devoid of any sensitivity as regards others?
In diametric opposition to your opinion, I am optimistic that the majority of investors, who have retained their shares, will recover their losses, although I cannot speculate as to how long it will take? Although it is your right to continue with your negativity, based on perfunctory lo- level obvious statements of events that have occurred in the last fortnight, it would be warmly appreciated if you were to take your unvalued opinions elsewhere.
Regards.
I do not view Jim Coyle's departure with the same state of trepidation as some contributors this morning. It is apparent that uninvested doomsayers are making a meal out of an insignificant event.
Jim Coyle is a highly respected figure in the banking industry, but retired from his major role with Lloyds Banking Group seven years ago following a successful spell with them spanning 25 years. He has a portfolio of directorships which he actively pursues, and are apparently a drain on his discretionary time. It is feasible that he took on his role with SYME for yet another payday. The company is in a state of ongoing development in preparing to launch a complex multi-layered innovative financial instrument. All this is highly demanding for a retired banker. It could well be the case that the additional burden of his involvement with a fledgling company was too much for Mr. Coyle?
As an investor, I wish that he had done the due diligence on the time needed for this additional commitment before getting involved. His sudden departure will have an impact on the share price, because nervous investors will only perceive it in the negative sense.
Over to you Alessandro Zamboni. You promised investors a strategic update by the end of the current month. I had hoped that Jim Coyle would be influential in this, but apparently this is no longer the case. Any more bluffing, and pointless and meaningless bluster, will no doubt have further dire consequences for the share price.
Good luck to all SYME investors. We really need it after yet another totally unnecessary setback.
Neither positive nor negative. Brooke Clarke has done the best she can with the information she has available to share. It continues to be a long hold for me, as I strongly believe in SNG001. The "deep dive" into the Sprinter trial data may lead to the emergence of some positive trends? Additionally, I shall continue to monitor Polygon's activity with interest, as this could lead to various possibilities in the mid - term?
This board has been a valuable information source over the last 18 months, and I shall continue to check in at quieter times. It is best left alone during trading hours for the time being. Already, at least one mindless cretin has inflicted her/his contemptible presence on this board this morning. These morons feature on most AIM boards. Their activity is characterised by their attempts to inflict maximum reduction in confidence on investors, with the minimum of effort. This suggests the they are paid minimal amounts to disrupt? Another consigned to a green coffin, but more will emerge when the market opens.
My best wishes to all Synairgen investors. Let us see what the market makes of Brooke's statement.
Currently 35.16% down on the day. We will learn why soon enough? The company is back to being an AIM minion. Investors' capital has literally flowed down the drain. Our hopes for and trust in this company have been vanquished. An RNS of some description will probably materialise soon explaining all. An indefinite hold for me, but any hope for a recovery later this year has gone. It would take something on the scale of the raising of Lazarus to turn the recent series of events around.
My best wishes to all fellow over-invested long term holders. I probably shan't visit this board for a while. It has been overrun by contributors whose priorities are very different to mine.
I agree with the points that Size82 has articulated so well this morning. Additionally, Kevin has raised something valuable in that bearing in mind the "choppy waters" the company has to navigate through, it really does need the right person to deliver the positive updates. The company has engaged the services of a media specialist with an appropriate pharmaceutical industry background. In my view, he would be the best person to pitch the updates when the company has them. Last Monday's RNS, and yesterday's e-mail from Brooke Clarke to shareholders conveyed the same information. The tone of the latter made a far more positive impression on me.
Good wishes to everyone. I look forward to a positive update, whenever it arrives.